Centessa Pharmaceuticals plc (NASDAQ:CNTA) Insider Sells $128,200.00 in Stock

Centessa Pharmaceuticals plc (NASDAQ:CNTA) insider Gregory M. Weinhoff sold 10,000 shares of Centessa Pharmaceuticals stock in a transaction dated Tuesday, May 27th. The shares were sold at an average price of $12.82, for a total value of $128,200.00. Following the transaction, the insider now owns 122,279 shares in the company, valued at $1,567,616.78. This trade represents a 7.56% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Centessa Pharmaceuticals Trading Up 1.4%

NASDAQ CNTA opened at $12.95 on Thursday. Centessa Pharmaceuticals plc has a 52 week low of $7.75 and a 52 week high of $19.09. The stock has a market capitalization of $1.73 billion, a price-to-earnings ratio of -8.46 and a beta of 1.53. The company has a debt-to-equity ratio of 0.15, a quick ratio of 21.52 and a current ratio of 21.52. The stock’s 50 day moving average price is $12.86 and its two-hundred day moving average price is $15.41.

Centessa Pharmaceuticals (NASDAQ:CNTA) last announced its quarterly earnings data on Monday, May 12th. The company reported ($0.20) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.35) by $0.15. As a group, analysts anticipate that Centessa Pharmaceuticals plc will post -1.6 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Centessa Pharmaceuticals

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Geode Capital Management LLC raised its stake in shares of Centessa Pharmaceuticals by 1.2% during the 4th quarter. Geode Capital Management LLC now owns 57,257 shares of the company’s stock worth $959,000 after purchasing an additional 660 shares in the last quarter. GF Fund Management CO. LTD. bought a new stake in shares of Centessa Pharmaceuticals during the 4th quarter worth approximately $31,000. Trexquant Investment LP raised its stake in shares of Centessa Pharmaceuticals by 1.1% during the 1st quarter. Trexquant Investment LP now owns 263,994 shares of the company’s stock worth $3,796,000 after purchasing an additional 2,810 shares in the last quarter. Caitong International Asset Management Co. Ltd raised its stake in shares of Centessa Pharmaceuticals by 15,209.5% during the 1st quarter. Caitong International Asset Management Co. Ltd now owns 3,215 shares of the company’s stock worth $46,000 after purchasing an additional 3,194 shares in the last quarter. Finally, Osterweis Capital Management Inc. bought a new stake in shares of Centessa Pharmaceuticals during the 1st quarter worth approximately $47,000. Institutional investors own 82.01% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on CNTA. Guggenheim reiterated a “buy” rating and set a $28.00 price objective on shares of Centessa Pharmaceuticals in a report on Wednesday, March 26th. Oppenheimer assumed coverage on Centessa Pharmaceuticals in a report on Thursday, May 8th. They set an “outperform” rating and a $6.00 price objective on the stock. Chardan Capital assumed coverage on Centessa Pharmaceuticals in a research note on Thursday, May 8th. They issued a “buy” rating and a $30.00 target price on the stock. Piper Sandler assumed coverage on Centessa Pharmaceuticals in a research note on Monday, March 31st. They issued an “overweight” rating and a $38.00 target price on the stock. Finally, Needham & Company LLC assumed coverage on Centessa Pharmaceuticals in a research note on Wednesday. They issued a “buy” rating and a $35.00 target price on the stock. One research analyst has rated the stock with a hold rating and ten have given a buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $27.89.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.